E
Enara Bio
Illuminating the immune interface to develop new cancer therapies - Enara Bio
About Enara Bio
Founded in 2016, Enara Bio emerged from Oxford, UK, with a mission to revolutionize cancer treatment through innovative immunotherapy solutions. The company was co-founded by a team of visionary scientists and entrepreneurs, including Kevin Pojasek, who played a pivotal role in steering the company towards its ambitious goals.
Enara Bio focuses on the discovery and development of Dark Antigens™, a novel class of immunotherapy targets that arise from the vast non-coding regions of the human genome. These targets are designed to improve treatment outcomes for a broad range of cancer patients, offering new hope in the fight against this pervasive disease.
In October 2024, Enara Bio reached a significant milestone by securing $32.5 million in Series B financing. This funding round was supported by a strong syndicate of new and existing investors, including notable names like Pfizer Ventures. The capital raised is intended to advance Enara Bio's pipeline of T-cell receptor-based immunotherapies, propelling the company closer to its goal of delivering first-in-class cancer treatments.
Enara Bio's journey is marked by its commitment to exploring the hidden depths of cancer biology and translating these discoveries into tangible therapies. As the company continues to innovate, it stands at the forefront of a new era in cancer treatment, driven by a deep understanding of the immune system's potential to combat disease.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Oxford, United Kingdom
- Employees
- 68
- Open positions
- None listed
- Dealroom signal
- 80.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, BIA Techbio UK, Techbio, Hard Tech, Techbio Drug Discovery, Digital Pharma, DT and LS, uk is8 life sciences
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Oct 2024 | $33M | $130M | SV Health Investors · The Francis Crick Institute · Samsara BioCapital · RA Capital Management | ↗ |
| SERIES AOther financing | Nov 2019 | $18M | $70M | SV Health Investors | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Enara Bio is 3.4K monthly website visits, up 78.9% over the last three months. Enara Bio's team grew 11.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
SV Health Investors
Pfizer
M Ventures
The Francis Crick Institute
Samsara BioCapital
RA Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Enara Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Enara Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.